Cargando…

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib

Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth challenged by neoadjuvant therapy. A model based on simplified assessment of tumor malignancy and pharmacodynamics efficiency was exercised to dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettini, Francesco, De Bonis, Maria Valeria, Strina, Carla, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Ciliberto, Ignazio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ungari, Marco, Locci, Mariavittoria, Paris, Ida, Scambia, Giovanni, Ruocco, Gianpaolo, Generali, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366144/ https://www.ncbi.nlm.nih.gov/pubmed/37488154 http://dx.doi.org/10.1038/s41598-023-38760-z

Ejemplares similares

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
por: Bernocchi, Ottavia, et al.
Publicado: (2021)

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

Microwave Assisted Extraction of Raw Alginate as a Sustainable and Cost-Effective Method to Treat Beach-Accumulated Sargassum Algae
por: Nesic, Aleksandra, et al.
Publicado: (2023)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

A case of trichogerminoma: a rare cutaneous follicular neoplasm
por: Ungari, Marco, et al.
Publicado: (2021)

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
por: Koukourakis, M I, et al.
Publicado: (2014)

Langerhans cell histiocytosis of an intra-mammary lymph node in an 18-year-old woman
por: Ungari, Marco, et al.
Publicado: (2020)

NeuN, a DNA-binding neuron-specific protein expressed by Merkel cell carcinoma: analysis of 15 cases
por: Ungari, Marco, et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study
por: Alborelli, Ilaria, et al.
Publicado: (2019)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
por: Fox, Stephen B, et al.
Publicado: (2011)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

A case of hand-foot syndrome with olaparib
por: da Costa, Rafael Everton Assunção Ribeiro, et al.
Publicado: (2022)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Perinatal depression during the fourth wave of the COVID-19 outbreak in a single prenatal clinic in Southern Italy: The role of loneliness, anxiety, and maternal support
por: Scandurra, Cristiano, et al.
Publicado: (2023)

8th International Workshop on Radiation Imaging Detectors
por: Bisogni, Maria Giuseppina, et al.
Publicado: (2007)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
por: Marra, A., et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu, Min, et al.
Publicado: (2018)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6o88bvbgd5s6lrt89svfpj6uk